Axcella Health Inc. (NASDAQ:AXLA) shares traded 2.41% higher at $0.43 on Wall Street last session.
In accordance with the data, 4 analysts cover Axcella Health Inc. (NASDAQ:AXLA). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $8.00 and a low of $1.50, we find $5.50. Given the previous closing price of $0.42, this indicates a potential upside of 1209.52 percent. AXLA stock price is now -32.88% away from the 50-day moving average and -73.37% away from the 200-day moving average. The market capitalization of the company currently stands at $32.86M.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
It has been rated a hold by 1 analysts and a buy by 3. Brokers who have rated the stock have averaged $5.13 as their price target over the next twelve months.
With the price target of $6, Noble Capital Markets recently initiated with Outperform rating for Axcella Health Inc. (NASDAQ: AXLA). On September 22, 2021, Goldman Downgraded its previous ‘Buy’ rating to ‘Neutral’ on the stock reducing its target price from $9 to quote $5, while ‘JP Morgan’ rates the stock as ‘Underweight’.
In other news, Hinshaw William, President & CEO sold 16,000 shares of the company’s stock on Oct 19. The stock was sold for $25,027 at an average price of $1.56. Upon completion of the transaction, the President & CEO now directly owns 82,012 shares in the company, valued at $35265.16. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 13, 10% Owner Flagship Ventures Fund IV Gene bought 10,383,760 shares of the business’s stock. A total of $17,029,366 was incurred on buying the stock at an average price of $1.64. This leaves the insider owning 14,101,638 shares of the company worth $6.06 million. Insiders disposed of 34,280 shares of company stock worth roughly $14740.4 over the past 1 year. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AXLA stock. A new stake in Axcella Health Inc. shares was purchased by THRIVENT FINANCIAL FOR LUTHERANS during the first quarter worth $15,000. COMMONWEALTH EQUITY SERVICES, LLC invested $9,000 in shares of AXLA during the first quarter. In total, there are 45 active investors with 46.60% ownership of the company’s stock.
Axcella Health Inc. (NASDAQ: AXLA) opened at $0.4000 on Monday. During the past 12 months, Axcella Health Inc. has had a low of $0.16 and a high of $2.89. The fifty day moving average price for AXLA is $0.6406 and a two-hundred day moving average price translates $1.6150 for the stock.
The latest earnings results from Axcella Health Inc. (NASDAQ: AXLA) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.4, missing analysts’ expectations of -$0.38 by -0.02. This compares to -$0.41 EPS in the same period last year. The company reported revenue of $17.09 million for the quarter, compared to $14.9 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 14.7 percent.
Axcella Health Inc.(AXLA) Company Profile
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
